Promoters for Glaucoma Gene Therapy
About the Research Project
Program
Award Type
Standard
Award Amount
$49,986
Active Dates
April 01, 1999 - March 31, 2001
Grant ID
G1999005
Summary
Gene therapy may prove to be an ideal form of treatment for diseases with genetic causes because a normal version of a gene could be introduced into cells to restore functions that have been disrupted due to the genetic mutation. If gene therapy is to be used one day for treating forms of glaucoma, two requirements must be met. First, one needs an efficient means, or vector, for placing genes in eye tissues. Second, genetic elements called promoters are required that will allow the therapeutic gene to be specifically turned on in the appropriate cell type (e.g. TM cells). Dr. Brandt has already attained the first goal and is now focused on identifying TM cell-specific promoters.
Related Grants
National Glaucoma Research
Reducing Inflammation to Protect Vision in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Cátia Gomes, PhD
Current Organization
Indiana University School of Medicine
Reducing Inflammation to Protect Vision in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Cátia Gomes, PhD
Current Organization
Indiana University School of Medicine
National Glaucoma Research
Novel Visualization of Aqueous Outflow: Uncovering Glaucoma Mechanisms and Therapeutic Targets
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Tyson Kim, MD, PhD
Current Organization
University of California, San Francisco
Novel Visualization of Aqueous Outflow: Uncovering Glaucoma Mechanisms and Therapeutic Targets
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Tyson Kim, MD, PhD
Current Organization
University of California, San Francisco
National Glaucoma Research
How Neural Activity Shapes Vision Recovery in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Yvonne Ou, MD
Current Organization
University of California, San Francisco
How Neural Activity Shapes Vision Recovery in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Yvonne Ou, MD
Current Organization
University of California, San Francisco